# PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer

> **NCT04301557** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 25 (estimated)

## Conditions studied

- DMMR Colorectal Cancer
- MSI-H Colorectal Cancer
- Locally Advanced Colorectal Cancer

## Interventions

- **DRUG:** PD-1 Antibody
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **RADIATION:** External beam radiotherapy
- **PROCEDURE:** Total mesorectal excision

## Key facts

- **NCT ID:** NCT04301557
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-31
- **Primary completion:** 2024-04-22
- **Final completion:** 2024-12-30
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04301557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04301557, "PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04301557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*